Copley Scientific Launches New Equipment to Streamline Inhaled Product Testing
Copley Scientific has launched a new instrument, the TPK-R critical flow controller model to improve the ergonomics of test set-up for dry powder inhaler (DPI) testing. The new unit frees up bench-space and simplifies connection of the key pieces of equipment routinely used for DPI testing, without compromising the validity of existing test methods.
Measuring the aerodynamic particle size distribution of DPIs helps to determine their in vivo behaviour and is essential during product development and for QC. Cascade impaction is the technique specified by the regulators, and the Next Generation Impactor (NGI) is routinely the instrument of choice for this application. Testing must be carried out at a constant, controlled air flow rate to ensure that the NGI delivers precise, calibrated performance.
Copley Scientific’s TPK Critical Flow Controllers incorporate all the functionality required to ensure the application of a stable, precisely defined flow profile, in a single integrated system. The TPK-R is a mirror image of the Critical Flow Controller Model TPK, which is already an industry standard, and has been designed specifically to match with the connection requirements of the NGI. It is identical to the TPK in all respects except for the inlet, outlet and user interfaces, which have all been reversed to connect more conveniently with the right-hand outlet of the NGI. Using the TPK-R therefore allows the more efficient use of laboratory bench space, without compromising the validity of existing test methods.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance